Neuronasal is leading the way in developing solutions for getting drugs delivered across the blood-brain-barrier and directly into the brain. It has a pre-clinical GLP-1 program with preferential brain delivery of existing GLP-1 drugs at lower doses that mitigate side effects but maintain efficacy. The company is also sponsoring three clinical trials for its patented direct nose-to-brain delivery of NAC (N-acetylcysteine) to treat Parkinson’s Disease. See Overview.
Strategic Partnerships
Ophidion
Technology collaboration — Enhanced brain delivery
- Co-development agreement signed
- Joint venture at preclinical stage
Cure Parkinson’s
Funding + clinical validation for Phase 2B N2B NAC
- External validation · Provides development funding
- De-risks clinical path to Phase 2B
Rubicon Research
Strategic investor + CMC manufacturing partner
- Ready to manufacture at scale
- Manufacturing de-risked
Beyond Barriers Therapeutics
Licensed mTBI program from Neuronasal · Phase 2
- Outlicensed – demonstrating independent third-party validation